Riassunto
Alla modificazione dei principali fattori di rischio comportamentali, alla diagnosi per immagini della placca e al suo trattamento chirurgico è necessario associare un controllo adeguato, anche con terapia farmacologica dove necessario, della pressione arteriosa, della dislipidemia, delle condizioni di iperglicemia e degli stati protrombotici e proinfiammatori. Una descrizione, seppur generale, dei farmaci utilizzati per prevenire tutti gli stati predisponenti/aggravanti la patologia aterosclerotica non rientra nello scopo del presente volume, ove verrà trattata solamente la terapia della dislipidemia, fattore coinvolto nell’eziopatogenesi della placca e in grado di influire anche sulla sua stabilità. Infatti, tanto più la placca è infarcita di colesterolo, tanto essa è instabile e propensa a rompersi, generando un evento cardiovascolare maggiore.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Bibliografia
Scheen AJ, Radermecker R, De Flines J, Ducobu J (2007) Recent treatment. Rev Med Liege 62:324–328
Silvestris F, Cafforio P, Campagna M (2004) Statins in clinical medicine: antiinflammatory and immunomodulatory effects. Giorn It Allergol Immunol Clin 14:59–67
Aronow WS (2006) Management of hyperlipidemia with statins in the older patient. Clin Interv Aging 1:433–438
Sheperd J, Cobbe SM, Ford I et al (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333:1301–1307
McTaggart F, Buckett L, Davidson R et al (2001) Preclinical and clinical pharmacology of Rovustatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol 87:28–32
Prevention of coronary heart disease in clinical practice. Recommendations of the second Joint Task Force of European and other Societies on coronary prevention (1998). Eur Heart J 19:1434–1503
Iughetti L, Predieri B, Balli F, Calandra S (2007) Rational approach to the treatment for heterozygous familial hypercholesterolemia in childhood and adolescence: a review. J Endocrinol Invest 30:700–719
Bloomfield Rubins H, Robins SJ, Collins D et al for the Veteran Affairs Hig h-Density Lipoprotein Chotesterol Intervention Trial Study Group (1999) Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Eng J Med 341:410–418
Scandinavian Simvastatin Survival Study Group (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383–1389
Goldberg RB, Mellies MJ, Sacks FM et al (1998) Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analysis in the cholesterol and recurrent events (CARE) trial: the CARE Investigators. Circulation 98:2513–2519
Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339:1349–1357
Downs JR, Clearfield M, Weis S et al (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA 279:1615–1622
Robins SJ, Collins D, Wittes JT et al (2001) VA-HIT Study Group. Veterans Affairs High-Density Lipoprotein Intervention Trial. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA. 285(12):1585–1591
Sever PS, Dalhof B, Poulter NR et al (2003) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower than average cholesterol concentrations, in the anglo-Scandinavian cardiac outcomes trial — Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 361:1149–1158
Rights and permissions
Copyright information
© 2010 Springer-Verlag Italia
About this chapter
Cite this chapter
(2010). Trattamento farmacologico. In: Aterosclerosi. Springer, Milano. https://doi.org/10.1007/978-88-470-1412-1_10
Download citation
DOI: https://doi.org/10.1007/978-88-470-1412-1_10
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-1411-4
Online ISBN: 978-88-470-1412-1
eBook Packages: MedicineMedicine (R0)